Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN 株式レポート

時価総額：US$305.3m

Eledon Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Eledon Pharmaceuticalsの CEO はDA Grosで、 Sep2020年に任命され、 の在任期間は 5.83年です。 の年間総報酬は$ 3.22Mで、 19.1%給与と80.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.012%を直接所有しており、その価値は$ 35.54K 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と5.7年です。

主要情報

DA Gros

最高経営責任者

US$3.2m

報酬総額

CEO給与比率19.07%
CEO在任期間5.8yrs
CEOの所有権0.01%
経営陣の平均在職期間5.3yrs
取締役会の平均在任期間5.7yrs

経営陣の近況

Recent updates

分析記事 • Mar 24

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • May 07

Companies Like Eledon Pharmaceuticals (NASDAQ:ELDN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jan 28

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Summary Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment. While it's too early for large investments, a small pilot position could be warranted based on promising early data and unmet medical needs. Read the full article on Seeking Alpha
Seeking Alpha • Oct 29

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Summary Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030. Positive data obtained from investigator-sponsored phase 1/2 trial, using tegoprubart for islet cell transplantation in patients with Type 1 Diabetes. Read the full article on Seeking Alpha
分析記事 • Mar 22

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Aug 10

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Apr 27

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jan 05

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 06

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

The shares of clinical-stage biotech Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) gained 10% in post-market trading Friday after the company announced that the FDA cleared its Investigational New Drug (IND) application for kidney disease therapy tegoprubart. Phase 2a trial for the candidate is currently underway globally, targeting patients with IgA Nephropathy, which can lead to End-Stage Renal Disease, dialysis, renal transplant, and death with a progressive impact on kidney function. With the IND clearance for tegoprubart in IgA, the company plans to open U.S. trial sites for the open-label study, which will enroll up to 21 patients worldwide in each of the two dose cohorts. Following regulatory clearance in 10 countries to study tegoprubart in IgA, ELDN plans to expand the trial to two more countries, including China. Early August, ELDN announced that the FDA greenlighted a mid-stage trial for tegoprubart as a treatment to prevent organ rejection in patients who underwent a kidney transplant.
分析記事 • Aug 31

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 01

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals (NASDAQ:ELDN) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application seeking to start a phase 2 trial of tegoprubart for preventing organ rejection in patients receiving a kidney transplant. The study will enroll ~120 people (60 in each group) undergoing kidney transplant  who will receive tegoprubart or the active comparator tacrolimus, sold as Prograf by Astellas Pharma (OTCPK:ALPMY) (OTCPK:ALPMF), as part of an immunosuppressive regimen including corticosteroids and mycophenolate mofetil or mycophenolate sodium. The trial's main goal is to assess superiority of graft function by comparing the mean estimated glomerular filtration rate (eGFR) at  12 months post-transplant in one group against the other. Secondary goals include safety, incidence of new onset diabetes, and participant and graft survival. "We believe strongly in tegoprubart’s potential to supplant CNIs in the immunosuppressive regimen of kidney transplant patients, potentially leading to reduced side effects such as diabetes and hypertension, better kidney allograft function, and a resulting longer functional life of transplanted kidneys," said Eledon CEO David-Alexandre Gros.
Seeking Alpha • Jul 18

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Pharmaceuticals (NASDAQ:ELDN) said the first patient was dosed in a phase 1b trial of tegoprubart in patients undergoing kidney transplantation. In the study, which received clearance in Canada and the U. K., is enrolling up to 12 patients who will undergo kidney transplantation and will receive tegoprubart in combination with rabbit anti-thymocyte globulin (rATG) induction, and mycophenolate mofetil and an oral steroid taper as maintenance therapy. "We believe tegoprubart has the potential to transform the clinical management of kidney transplantation by preventing graft rejection, mitigating the multiple toxicities associated with CNIs, and ultimately improving long term outcomes," said Eledon CEO David-Alexandre Gros. In June, the U.S. Food and Drug Administration granted orphan drug designation to tegoprubart for preventing allograft rejection in pancreatic islet cell transplantation.
分析記事 • Apr 14

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Feb 21

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

A look at the shareholders of Eledon Pharmaceuticals, Inc. ( NASDAQ:ELDN ) can tell us which group is most powerful...
分析記事 • Dec 30

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO報酬分析

Eledon Pharmaceuticals の収益と比較して、DA Gros の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$78m

Dec 31 2025US$3mUS$613k

-US$46m

Sep 30 2025n/an/a

-US$83m

Jun 30 2025n/an/a

US$15m

Mar 31 2025n/an/a

-US$19m

Dec 31 2024US$6mUS$582k

-US$36m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$128m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$3mUS$559k

-US$117m

Sep 30 2023n/an/a

-US$145m

Jun 30 2023n/an/a

-US$145m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$1mUS$533k

-US$88m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$748kUS$504k

-US$35m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$7mUS$150k

-US$23m

報酬と市場: DAの 総報酬 ($USD 3.22M ) は、 US市場 ($USD 2.46M ) の同規模の企業の平均を上回っています。

報酬と収益: DAの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

DA Gros (54 yo)

5.8yrs
在職期間
US$3,216,148
報酬

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
David-Alexandre Gros
CEO & Non Independent Director5.8yrsUS$3.22m0.012%
$ 35.5k
Steven Perrin
President5.8yrsUS$1.70m0.0013%
$ 3.9k
Paul Little
Chief Financial Officer5.3yrsUS$1.59m0.013%
$ 39.5k
John Herberger
Vice President of Technical Operationsno dataデータなしデータなし
Bryan Smith
General Counsel5.3yrsUS$1.68mデータなし
David Hovland
Chief Regulatory Officer5.3yrsデータなしデータなし
Marina Escudero
VP & Head of Clinical Operations2.5yrsデータなしデータなし
5.3yrs
平均在職期間
57yo
平均年齢

経験豊富な経営陣: ELDNの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称ポジション在職期間報酬所有権
David-Alexandre Gros
CEO & Non Independent Director5.8yrsUS$3.22m0.012%
$ 35.5k
Steven Perrin
President5.8yrsUS$1.70m0.0013%
$ 3.9k
Keith Katkin
Independent Chairman of the Board9.2yrsUS$487.71k0.012%
$ 36.5k
John McBride
Independent Director9.2yrsUS$192.25k0.0044%
$ 13.6k
James Robinson
Independent Director2.8yrsUS$189.41k0.0044%
$ 13.6k
Jan Hillson
Independent Director5yrsUS$175.21k0.0044%
$ 13.6k
June H. Lee
Independent Director5.6yrsUS$192.25k0.0044%
$ 13.6k
Allan Kirk
Independent Director2.8yrsUS$183.14k0.0044%
$ 13.6k
5.7yrs
平均在職期間
60yo
平均年齢

経験豊富なボード: ELDNの 取締役会 は 経験豊富 であると考えられます ( 5.7年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/05 02:40
終値2026/07/02 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Eledon Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Edward WooAscendiant Capital Markets LLC
Alethia YoungCantor Fitzgerald & Co.
Pete StavropoulosCantor Fitzgerald & Co.